|
|
|
Abbott Launches TriMaxx™ Coronary Stent and
Five New Products for Vascular Intervention at Paris Course on Revascularization Newly Available TriMaxx™ Coronary Stent, Designed for Optimal Deliverability and Enhanced Visibility, Also Serves As Platform for Abbott’s Investigational Drug-Eluting Stent PARIS, France, May 25, 2005 - Abbott Vascular, a division of Abbott, today announced the launch of six new interventional cardiovascular products in Europe with CE Mark approval. Adding to its comprehensive line of vessel treatment products, Abbott launched its next-generation coronary stent, TriMaxx™, the platform for its much-anticipated investigational drug-eluting stent, ZoMaxx™, in Europe today at The Paris Course on Revascularization (PCR). Also at PCR, Abbott unveiled a new Non-Compliant (NC) Mercury™ Coronary Balloon Catheter for high-pressure post-dilation of coronary stents; the Xceed™ Vascular Nitinol Self-Expanding Stent with single-handed deployment; the Xpert™ Vascular Self-Expanding Stent offering 4 French (F) sheath compatibility; and the Fox™ Plus and Fox™ sv PTA Catheters featuring advanced dual lumen design for rapid balloon inflation and deflation. "Physicians in Europe will appreciate TriMaxx' unique stainless steel and tantalum tri-layer design," said Chip Hance, president, Abbott Vascular. "Along with the introduction of TriMaxx, the European launch of five additional products demonstrates our continuing commitment to deliver high-performing technology that can be relied upon by physicians to build their interventional practices. All of our products, including our flagship StarClose™ Vascular Closure System, are developed with the core intention of improving patient outcomes and enhancing quality of life." Presenting on his experience with the TriMaxx coronary stent, Alexandre Abizaid, M.D., of Dante Pazzanese Hospital in São Paulo, Brazil, will speak in the "Preparing for the Next Generation of DES" symposium at PCR on Wednesday, May 25th, 2005, at 4:30 pm in Room 3 at the Palais des Congres. "In my experience, Abbott's TriMaxx stent offers an excellent level of deliverability," said Dr. Abizaid. "Its thin low-profile design, coupled with the ability to clearly see the product under angiogram (X-ray), should make the TriMaxx a compelling candidate for everyday use and for accurate stent placement in certain challenging cases." Dr. Abizaid has worked with the TriMaxx since 2004 and was the first physician to implant the TriMaxx in patients with diseased coronary arteries. About The TriMaxx Coronary Stent The TriMaxx Coronary Stent has extremely thin struts (mesh scaffolding) and an ultra-low crossing profile designed to facilitate stent placement in arteries. Abbott launched the TriMaxx coronary stent in Europe with a full matrix of sizes including stent diameters ranging from 2.25 mm to 4.0 mm, and lengths ranging from 8 mm to 28 mm. TriMaxx is the first and only bare metal stent platform developed with a tri-layer composite of stainless steel and tantalum designed to enable optimal visibility under X-ray fluoroscopy. About The NC (Non-Compliant) Mercury Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Non-compliant refers to a balloon catheter's controlled expansion at high-pressures. Such controlled expansion can help prevent over-inflation during surgery, potentially enhancing patient safety. The NC Mercury balloon is intended to allow physicians to reliably and confidently use high pressure to post-dilate coronary stents. The NC Mercury provides the potential for optimal coronary stent expansion with enhanced material integrity. With the low growth non-compliant balloon material, OptiLiance™, the NC Mercury delivers flat compliance characteristics with high rate of burst pressure (up to 20 bar) for 2.5 mm to 4.5 mm expansion potential. The NC Mercury adds to Abbott Vascular's full balloon angioplasty offering, including the workhorse balloon, Mercury, and the MaestroX™, a specialty balloon designed for highly stenosed lesions. About The Xceed Nitinol Vascular Self Expanding Stent The Xceed Nitinol Self Expanding Stent features Freestyle™ Technology, a proprietary delivery system intended to provide physicians with outstanding placement accuracy using single-handed deployment. The Freestyle delivery system design is highly flexible and deliverable, and is intended to allow for smooth tracking through challenging anatomies. About The Xpert Vascular Self Expanding Stent The Xpert Self Expanding Stent system currently offers the lowest profile and smallest sizes (3mm and 4mm diameter) of any self-expanding stent on the market, and is the only stent of its kind to offer 4 French sheath compatibility for true support of 4F diagnostic and interventional procedures. Xpert is designed to allow physicians to treat complex small vessel disease. About The Fox Plus PTA Catheter The Fox Plus PTA Catheter offers interventionalists a reliable solution for the challenges of percutaneous transluminal angioplasty (PTA), balloon dilation of narrowed arteries. The Fox Plus PTA Catheter features an advanced dual lumen design to allow for rapid balloon inflation and deflation. Its low profile, tapered tip, and SLIC™ hydrophilic coating provide for excellent deliverability. The Fox Plus PTA Catheter combines these attributes with a unique balloon material that delivers controlled compliance and rated burst pressures of up to 18 bar. About The Fox sv PTA Catheter The Fox sv PTA Catheter offers a solution for treating small vessels with percutaneous transluminal angioplasty (PTA). With sizes ranging from 2 mm to 5 mm in diameter, Fox sv is designed to support true 4F diagnostic and interventional procedures with 0.018 guidewire capability, a tapered tip, SLIC hydrophilic coating, and unique balloon material that delivers controlled compliance and rated burst pressures of up to 18 bar. Featuring the same dual lumen design offered with Fox Plus, that is intended to allow for rapid balloon inflation and deflation, Fox sv is designed to provide physicians with wide versatility and excellent deliverability. About Abbott Vascular Abbott Vascular, a division of Abbott, is transforming the treatment of vascular disease, combining the latest medical device innovations with world-class pharmaceuticals to advance medicine and improve patient care. Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety, ease of use and effectiveness in treating patients with vascular disease. Abbott Vascular is headquartered in Redwood City, Calif. For more information about Abbott Vascular, visit www.abbottvascular.com. About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com . ZoMaxx, TriMaxx, Mercury, OptiLiance, MaestroX, Xceed, Xpert, Fox, Freestyle, and SLIC are trademarks of Abbott. StarClose is currently available for sale in Europe under CE Marking. StarClose is an investigational device in the U.S., limited by Federal (or United States Law) to investigational use. source: Abbott |
Angioplasty.Org Home • PatientCenter
this press release is posted as a reader
service by Angioplasty.org,
an editorially independent informational health
site
which has received unrestricted educational grants from
Medtronic plc,
TCROSS NEWS, Toshiba
America
Medical Systems, Volcano
Corporation, Terumo
Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2021
